Britt questions witnesses on efforts to lower prescription drug costs

Witnesses outlined trade-offs in patient cost caps, threats to independent pharmacies and proposals to pass drug discounts directly to consumers.

Sen. Katie Britt during a Senate committee hearing.
Sen. Katie Britt during a Senate committee hearing.

U.S. Senator Katie Britt, R-Alabama, asked witnesses at a Senate Judiciary Committee hearing Tuesday which recent measures had lowered prescription drug costs and where Congress could do more.

Britt pointed to Medicare drug price negotiations and new transparency requirements for pharmacy benefit managers among the steps federal officials have taken in recent years.

Neeraj Sood, a University of Southern California professor, said caps on insulin copays and out-of-pocket spending under Medicare Part D have helped patients at the pharmacy counter. He said capping out-of-pocket costs can also drive up premiums and urged lawmakers to base patients’ share of drug costs on prices after rebates.

Karriem Watson, CEO of UI Health Mile Square Health Center, called for reimbursement rates that cover what rural and independent pharmacies pay for medications. Matthew Pitlick, CEO of the Iowa Pharmacy Association, said state laws mandating dispensing fees can leave patients paying those fees unless the laws include safeguards.

Alex Oshmyansky, co-founder and CEO of the Mark Cuban Cost Plus Drug Company, called for separating pharmacies from pharmacy benefit managers. Merith Basey, CEO of Patients for Affordable Drugs Now, urged lawmakers to scrutinize the prices drugmakers set when they bring medications to market.

“We’ve got to make sure that our rural and independent pharmacies not only survive, but thrive,” Britt said. “And we need to make sure that the cost savings are passed to the actual consumer.”